Investors

Corporate Profile

Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.

Corporate Investor Presentation

Rigel Corporate Investor Presentation

Date	Title
10/11/18	Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients First SYK inhibitor for the treatment of adult chronic ITP SOUTH SAN FRANCISCO, Calif. , Oct. 11, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for fostamatinib
09/27/18	Rigel to Host Investor & Analyst Day in New York City on October 4, 2018 SOUTH SAN FRANCISCO, Calif. , Sept. 27, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) today announced that it will host an investor and analyst day event on Thursday, October 4, 2018 from 12:00pm to 2:30pm Eastern Time in New York City .
09/24/18	Rigel to Present at the Cantor Global Healthcare Conference SOUTH SAN FRANCISCO, Calif. , Sept. 24, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and chief executive officer, is scheduled to present a company overview at the Cantor Global Healthcare Conference in New York City

Stock Quote

(Common Stock)
Exchange	(US Dollar)
Price
Change (%)
Volume
Data as of

E-mail Alerts

Click here to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site

Investors

Investors

Corporate Profile

Corporate Investor Presentation

Stock Quote

Stock Chart

E-mail Alerts